Teva Pharmaceutical Industries Ltd Announces Important Development

Teva Pharmaceutical Industries Ltd recently revealed that Richard Francis, the company’s President and CEO, is set to take the stage at two investor conferences in November. The first conference, the UBS Global Healthcare Conference, is scheduled for Monday, November 10, 2025, at 8:45 A.M. Eastern Time (ET). The second is the Jefferies London Healthcare Conference, to be held on Tuesday, November 18, 2025, at 11:00 A.M. Greenwich Mean Time (6:00 A.M. ET).

Audiences interested in tuning in to the presentation can access a live webcast of the event on Teva’s Investor Relations website. For an archived version of the webcast, individuals can revisit the site within 24 hours of the live discussion’s conclusion.

Teva Pharmaceutical Industries Ltd, traded on the NYSE and TASE under the symbols TEVA, holds a prominent position in the biopharmaceutical field, boasting a top-tier generics business. With a legacy spanning over 120 years, Teva remains steadfast in its commitment to advancing healthcare. Delving into cutting-edge work in neuroscience and immunology, Teva also supplies a wide range of generic medications, biosimilars, and pharmacy brands across the globe. The company’s primary aim is to cater to the evolving needs of patients, both in the present and future. In the words of Teva, “We Are All In For Better Health.”

A word of caution is necessary when delving into discussions at these conferences and reviewing related documents. The content may contain forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Management’s current beliefs and expectations serve as the basis for these statements, but they are subject to significant risks and uncertainties. Factors both known and unknown could potentially drive substantial disparities between the anticipated results, performance, or achievements and the actual outcome. It is imperative to remain vigilant when considering these forward-looking statements, denoted by phrases such as “expect,” “anticipate,” “intend,” and “believe.” The company does not undertake an obligation to revise or update any forward-looking statements or related information, regardless of new developments, future events, or other catalysts.

Candidates can get in touch with Teva for media inquiries at [email protected] and with Teva’s Investor Relations team at [email protected]. Enthusiasts can subscribe to Globenewswire releases by sharing their email for updates.